{name}
{subtitle}
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
city
~30 mi. (Ravensburg, Germany, +144 more cities)
facility
GSK Investigational Site
drug
carboplatin, +3 more drugs
drug type
chemotherapy, +2 more types
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
city
~30 mi. (Ravensburg, Germany, +170 more cities)
facility
Novartis Investigative Site
biomarker
ER Negative, +4 more biomarkers
drug
alpelisib, +1 more drug
drug type
chemotherapy, +1 more type
Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002)
city
~30 mi. (Ravensburg, Germany, +76 more cities)
facility
Onkologie Ravensburg ( Site 1104)
drug
docetaxel, +1 more drug
drug type
chemotherapy, +1 more type
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
city
~38 mi. (Eßlingen, Germany, +145 more cities)
facility
Klinikum Esslingen-Klinik für Kardiologie und Pneumologie ( Site 1208)
drug
pembrolizumab, +1 more drug
drug type
immunotherapy, +2 more types
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~47 mi. (Tübingen, Germany, +226 more cities)
facility
Universitaetsklinik fuer Urologie ( Site 0307)
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~47 mi. (Tübingen, Germany, +93 more cities)
facility
Universitaetsklinik fuer Urologie ( Site 0501)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
city
~47 mi. (Tübingen, Germany, +159 more cities)
facility
Klinikum der Eberhard-Karls-Universitaet Tuebingen ( Site 0502)
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +1 more type
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
city
~47 mi. (Tübingen, Germany, +163 more cities)
facility
Klinikum der Eberhard-Karls-Universitaet Tuebingen ( Site 0549)
drug
cystectomy, +2 more drugs
drug type
chemotherapy, +3 more types
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
city
~47 mi. (Tübingen, Germany, +150 more cities)
facility
Universitaetsklinikum Tuebingen - Medizinische Klinik ( Site 0401)
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +2 more types
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~47 mi. (Tübingen, Germany, +137 more cities)
facility
Universitaetsklinikum Tuebingen ( Site 0409)
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)
city
~47 mi. (Tübingen, Germany, +127 more cities)
facility
Universitaetsklinikum Tuebingen ( Site 2108)
drug
lenvatinib, +1 more drug
drug type
immunotherapy, +1 more type